The Dems' Reactions to Trump's Iran Strikes Proves Again That They Can't Be...
Whose Side Are Democrats Really On?
Can the Left Ever Stop Its Craziness?
The Media Bombs With Its Coverage of the Iran Attack and Leaves Smoldering...
NYC Mayor's Race Watch: A Referendum on National Housing Policy?
A Wise and Frugal Government We Do Not Have, Nor a Virtuous One
Trump Did the Right Thing
There's Nobody to Talk to
The ‘First String’ Is Back in the Game
With Iran Destabilizing the Middle East, American Energy Is More Important Than Ever
Three Years Since Dobbs and the World’s Still Turning
The Senate Must Act to Bring College Costs Under Control
Three Years After Dobbs, the Result Is a Tale of Two Very Different...
One Big, Beautiful Bill: A Blueprint for America's Comeback
Hours After Trump Declares Ceasefire, Iran Denies Agreement, Blames Israel for Starting Wa...
Tipsheet

The FDA Just Approved This Surprising Standalone Treatment for Depression

AP Photo/Andrew Harnik, File

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray to be used alone in adults with major depressive disorder. 

Advertisement

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression. This is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.

According to CNBC, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing thoughts of suicide or harm. 

“We want to recognize that this is a medicine that treats a disease that [when] left untreated, depression is potentially fatal,” Bill Martin, J&J’s global therapeutic area head of neuroscience, said in an interview with the outlet.

Advertisement

Reportedly, about one-third of the estimated 21 million U.S. adults with major depression battle symptoms don’t respond to treatment.

“For the first time ever, we now have an option that gives patients freedom,” Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said. 

Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren’t improving their symptoms and are causing undesirable side effects.

The approval of Spravato was based on a phase four trial that showed that Spravato alone improved depressive symptoms beginning about 24 hours after treatment and lasting through at least one month. The drug first entered the US market in 2019.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement